Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study

Area of Science:

• Nephrology
• Infectious Diseases
• Pharmacology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia poses significant treatment challenges.
• Vancomycin is a primary antibiotic for MRSA infections, but its nephrotoxicity is a concern.
• Acute kidney injury (AKI) is a common and serious complication in hospitalized patients.

Purpose of the Study:

• To investigate the relationship between vancomycin exposure and AKI in patients with MRSA bacteremia.
• To assess the impact of flucloxacillin on AKI rates in this patient population.
• To identify specific vancomycin exposure thresholds associated with increased AKI risk.

Main Methods:

• Prospective randomized clinical trial involving patients with MRSA bacteremia.
• Monitoring of vancomycin exposure, including area under the curve (AUC).
• Assessment of AKI incidence and its association with antibiotic treatment and exposure levels.

Main Results:

• AKI rates increased with higher vancomycin exposure, even within the therapeutic range.
• The flucloxacillin group experienced a higher incidence of AKI independently.
• A vancomycin AUC of ≥470 mg·h/L on Day 2 was significantly associated with AKI, irrespective of flucloxacillin use.

Conclusions:

• Vancomycin exposure is a significant risk factor for AKI in MRSA bacteremia patients.
• Flucloxacillin may also contribute to AKI development.
• Optimizing vancomycin dosing and considering alternative therapies may be crucial for preventing AKI.